Amphotericin B Colloidal Dispersion
PreclinicalSmall molecule
Amphotericin B Colloidal Dispersion is one of 15 small molecule programs targeting Cryptococcal Meningitis. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
23 competitors in Cryptococcal Meningitis
#DrugCompanyPhaseTrials
1Abelcet
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Zoloft
VViatris Specialty LLC
Phase 3
Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Nolvadex
AstraZenecaPhase 2
Actimmune
HHorizon Therapeutics Ireland DAC
Phase 2
Decadron
AAspen Global Incorporated
Phase 2
Vivjoa
MMycovia Pharmaceuticals Inc.
Phase 3
Vfend
PPrism Pharmaceuticals
Phase 1
MAT2203
MMatinas BioPharma Nanotechnologies, Inc.
Phase 3
Ancobon
BBausch Health Americas, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details